COMPANY PROFILE

Merganser Biotech

Explore full profile

Research company that is engaged in the development and licensing of medicines

Kline Township, United StatesFounded 2011Biotech & Life Sciences

Valuation $100–250M Last recorded · 2015

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Merganser Biotech

Merganser Biotech is a leading provider of timely and accurate news coverage on significant events and breakthroughs in the biotechnology sector. The company focuses on a wide range of topics including innovative gene editing technologies like CRISPR Cas9, advancements in personalized medicine, regenerative therapies, and agricultural biotechnology. Merganser Biotech serves a diverse clientele comprising seasoned professionals, dedicated researchers, industry investors, and biotechnology enthusiasts. Operating in the biotechnology news and analysis market, the business model revolves around delivering expert opinions, thought leadership, and insights into the latest trends and ideas driving innovation in the field. Revenue is generated through subscriptions, advertising, and sponsored content. The company also explores advancements in bioinformatics and computational biology, including machine learning algorithms for drug discovery and genomic data analysis.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2011
Headquarters: Kline Township, United States
Employees: 1
Open positions: None listed
Dealroom signal: 22.3/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCEquity / VC	Dec 2016	$0	—	Undisclosed	—
SERIES A✓Equity / VC	Feb 2015	$28M	$112M	Novartis Venture Fund	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Merganser Biotech website traffic

Latest recorded traffic for Merganser Biotech is 170 monthly website visits. Merganser Biotech's team grew 0% over the past year.

Latest monthly visits170 1-year team growth0%

Monthly website visitsOct 2017–May 2020

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
OCOne CuregenDeveloping diverse technologies necessary for the development of first-in-class global anticancer drugs	Daejeon, South Korea	Operational	—	—	—
INInGenoCreated diagnostic and therapeutic solutions that, starting from DNA, allow to personalize treatments	Milan, Italy	Operational
ESEmerald Health SciencesAdvancing the pharmaceutical development of cannabinoid based molecules for the treatment of human disease	Vancouver, Canada	Operational
SBSalish BioscienceAn oncology diagnostics company focused on answering the question, "do I still have cancer?"	Seattle, United States	Operational
WEWethrivvScience-based company focused on hair growth and post procedure skincare	Doylestown, United States	Operational
CTClairvoyant TherapeuticsProvides evidence-based psychedelic therapy to help patients live healthier and enriched lives	Vancouver, Canada	Acquired
CACalmigoOffers an innovative drug free solution device providing immediate relief of anxiety and anxiety attacks	New York City, United States	Operational
CTCyrano TherapeuticsSensory Disorder \| Loss of Taste & Smell \| Smell and Taste Disorders	Delray Beach, United States	Operational